Dr Reddy's Laboratories Ltd
NSE:DRREDDY
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 062.5901
1 411.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Dr Reddy's Laboratories Ltd
Dr Reddy's Laboratories Ltd
Other Current Liabilities
Dr Reddy's Laboratories Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Other Current Liabilities
₹55.7B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Other Current Liabilities
₹25.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Other Current Liabilities
₹93.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
15%
|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Other Current Liabilities
₹11.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
2%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Other Current Liabilities
₹10.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Other Current Liabilities
₹8.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Dr Reddy's Laboratories Ltd
Glance View
Dr. Reddy's Laboratories Ltd., a prominent player in the global pharmaceutical landscape, has carved out a distinguished reputation for its commitment to producing high-quality medicines and innovative healthcare solutions. Founded in 1984 by Dr. K. Anji Reddy in Hyderabad, India, the company has expanded its reach across over 100 countries, including significant markets in the United States, Russia, and Europe. With a diverse portfolio that encompasses generic medications, active pharmaceutical ingredients (APIs), and proprietary pharmaceutical products, Dr. Reddy's stands as a reliable source for affordable healthcare options. Fuelled by a strong focus on research and development, the company invests heavily in cutting-edge technology and strives to address unmet medical needs in therapeutic segments such as oncology, cardiovascular disorders, and diabetes. For investors, Dr. Reddy's represents a robust opportunity in the fast-evolving healthcare sector. The company has consistently demonstrated resilience through its strategic alliances, a strong regulatory track record, and a growing pipeline of products. With the global generics market projected to expand significantly, Dr. Reddy's is well-positioned to leverage its expertise and operational efficiencies to capture new growth avenues. The company's emphasis on sustainability and corporate governance, exemplified by its responsible business practices, further enhances its appeal. With a strategic vision aimed at becoming a leading player in the pharmaceutical industry, Dr. Reddy's Laboratories is not just a company; it's a narrative of innovation and opportunity for investors seeking to make a meaningful impact in the healthcare domain.
See Also
What is Dr Reddy's Laboratories Ltd's Other Current Liabilities?
Other Current Liabilities
55.7B
INR
Based on the financial report for Jun 30, 2024, Dr Reddy's Laboratories Ltd's Other Current Liabilities amounts to 55.7B INR.
What is Dr Reddy's Laboratories Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
11%
Over the last year, the Other Current Liabilities growth was 10%. The average annual Other Current Liabilities growth rates for Dr Reddy's Laboratories Ltd have been 12% over the past three years , 11% over the past five years .
You don't have any saved screeners yet
